| 李 昊,王建忠,何春艳,林 涛,刘 望,陆婉玲.血清cfDNA、VEGFA与晚期胃癌患者化疗疗效和预后的关系研究[J].现代生物医学进展英文版,2023,(18):3510-3513. |
| 血清cfDNA、VEGFA与晚期胃癌患者化疗疗效和预后的关系研究 |
| Study on the Relationship between Serum cfDNA, VEGFA and Chemotherapy Efficacy and Prognosis in Patients with Advanced Gastric Cancer |
| Received:March 03, 2023 Revised:March 27, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.18.021 |
| 中文关键词: cfDNA VEGFA 晚期胃癌 疗效 预后 |
| 英文关键词: cfDNA VEGFA Advanced gastric cancer Efficacy prognosis |
| 基金项目:陕西省重点研发计划项目（S2020-YF-YBSF-0777) |
|
| Hits: 622 |
| Download times: 432 |
| 中文摘要: |
| 摘要 目的：研究血清循环游离脱氧核糖核酸（cfDNA）、血管内皮生长因子A（VEGFA）与晚期胃癌患者化疗疗效和预后的关系。方法：选取2018年6月~2020年6月在空军第九八六医院接受含奥沙利铂方案化疗的晚期胃癌患者108例，所有患者均接受含奥沙利铂方案化疗，化疗2个周期后，根据实体瘤疗效评价标准（RECIST）1.1版评估疗效分为敏感组和不敏感组，比较两组血清cfDNA、VEGFA水平；随访24个月，Kaplan-Meier生存曲线分析血清cfDNA、VEGFA高表达和低表达组的总生存期（OS），采用Cox风险比例模型进行预后多因素分析。结果：不敏感组血清cfDNA、VEGFA水平显著高于敏感组（P＜0.05）。cfDNA、VEGFA高表达组患者中位OS均明显短于cfDNA、VEGFA低表达组（P＜0.05）。Cox回归模型单因素分析显示，性别、年龄、部位与晚期胃癌预后无关（P＞0.05），而TNM分期Ⅳ期、分化程度低分化、有淋巴结转移、化疗疗效不敏感、cfDNA高水平、VEGFA高水平与晚期胃癌预后差显著相关（P＜0.05）。Cox回归模型多因素分析显示，淋巴结转移、化疗疗效不敏感及cfDNA、VEGFA水平高是晚期胃癌患者预后的危险因素（P＜0.05）。结论：血清cfDNA、VEGFA水平检测有助于晚期胃癌患者化疗疗效监测和预后评估。 |
| 英文摘要: |
| ABSTRACT Objective: To study the relationship between serum circulating free deoxyribonucleic acid (cfDNA), vascular endothelial growth factor A (VEGFA), and the chemotherapy efficacy and prognosis in patients with advanced gastric cancer. Methods: A total of 108 patients with advanced gastric cancer who received chemotherapy with oxaliplatin regimen at the 986th Air Force Hospital from June 2018 to June 2020 were selected. All patients received chemotherapy with oxaliplatin regimen. After two cycles of chemotherapy, they were divided into sensitive and insensitive groups according to the Solid Tumor Efficacy Evaluation Standard (RECIST) version 1.1, and their serum cfDNA and VEGFA levels were compared between the two groups; Follow up for 24 months, Kaplan Meier survival curve analysis was performed on the total survival time (OS) of serum cfDNA and VEGFA high expression and low expression groups, and a Cox risk proportional model was used for prognostic multivariate analysis. Results: The serum cfDNA and VEGFA levels in the insensitive group were significantly higher than those in the sensitive group (P<0.05). The median OS of patients with high expression of cfDNA and VEGFA was significantly shorter than that of patients with low expression of cfDNA and VEGFA (P<0.05). Cox regression model univariate analysis showed that gender, age, and location were not associated with the prognosis of advanced gastric cancer (P>0.05), while TNM stage IV, low differentiation, lymph node metastasis, insensitive chemotherapy efficacy, high levels of cfDNA, and VEGFA were significantly correlated with poor prognosis of advanced gastric cancer (P<0.05). Cox regression model multivariate analysis showed that lymph node metastasis, insensitivity to chemotherapy efficacy, and high levels of cfDNA and VEGFA were risk factors for the prognosis of advanced gastric cancer patients (P<0.05). Conclusion: The detection of serum cfDNA and VEGFA levels is helpful for monitoring chemotherapy efficacy and evaluating prognosis in advanced gastric cancer patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
